Asset profile
Anitocabtagene autoleucel
Cell therapy
Evidence outlook · registrational
Multiple Myeloma: registrational readout pending
Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2028-07.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
92 competitors in this universe: 32 direct rivals (same mechanism and indication), 0 same-class, 60 same-indication; 23 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Anitocabtagene Autoleucel: this drug | Phase 3 | Cell therapy | BCMA | ||
| Belantamab Mafodotin | Approved | Antibody–drug conjugate | BCMA | ||
| Ciltacabtagene Autoleucel | Approved | Cell therapy | BCMA | ||
| Idecabtagene Vicleucel | Approved | Cell therapy | BCMA | ||
| Equecabtagene Autoleucel | Phase 3 | Cell therapy | BCMA | ||
| HRC0202 | Phase 2 | Cell therapy | BCMA | ||
| PHE885 | Phase 2 | Cell therapy | BCMA | ||
| AZD4045 | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA CAR-NK (Hrain) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA CAR-NK (Shenzhen Pregene Biopharma) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-CART (Bioray Laboratories) | Phase 1/2 | Cell therapy | BCMA | ||
| BCMA-Targeted Prime CAR-T Cells (Chongqing Precision Biotech) | Phase 1/2 | Cell therapy | BCMA | ||
| GSK2857914 | Phase 1/2 | Monoclonal antibody | BCMA | ||
| Pamlectabart Tismanitin | Phase 1/2 | Adc (anti-bcma Antibody-targeted Amanitin Conjugate) | BCMA | ||
| SENL103 | Phase 1/2 | Cell therapy | BCMA | ||
| Trovocabtagene Autoleucel (C-CAR088) | Phase 1/2 | Cell therapy | BCMA |
…and 77 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
8 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
March 2027 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.